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A B S T R A C T
Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time
when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated com-
plications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown pro-
mising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in
many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of
the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and
thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy
response and timely treatment modification in the context of disease relapse. Here, we review recent reports of
the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We
critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid
biopsies can be implemented in routine clinical practice for OC management.
1. Introduction
Ovarian cancer (OC) is the 7th most common cancer and the 8th
leading cause of cancer mortality in women world-wide [1]. OC can be
cured in up to 90% of cases, if diagnosed while still limited to the
ovaries. However, due to lack of effective screening tests and absence of
clinical symptoms in early stage disease, approximately 70% of patients
with OC are diagnosed at advanced stages (stage III and IV). Late stage
OC is associated with poor prognosis despite best therapeutic efforts
with cytoreductive surgery and systematic chemotherapy [2,3]. Thus,
an efficient method for early detection and monitoring of disease pro-
gression or relapse may improve the survival outcomes and manage-
ment of OC patients.
Neoplasms of the ovary are diagnosed and monitored by conven-
tional tissue biopsy method, transvaginal ultrasound (TVUS), compu-
terised tomography (CT) scan, positron emitting tomography (PET),
and a blood test for the detection of the membrane glycoprotein, Muc-
16, also known as cancer antigen-125 (CA-125) [4]. Imaging studies
can help identify observable cell mass in the ovary or other sites, but do
not provide a clear diagnosis nor differentiate between malignant or
benign lesions [5]. Moreover, the detection of possible metastasis at
other sites may be elusive or undetectable until reaching a sufficient
size. Tissue biopsy on the other hand can be challenging, invasive and
does not reveal tumor heterogeneity [6]. CA-125 is the best char-
acterized biomarker for OC, and currently the clinical standard for
disease monitoring [4]. However, CA-125 lacks specificity as a
screening tool, since it can be elevated in other benign (endometriosis
and pelvic inflammatory diseases) and malignant tumors (breast, lung
and gastrointestinal cancers) [7–10]. Thus, CA-125 is useful for disease
and treatment monitoring, but unreliable for screening or initial diag-
nosis of OC. The use of novel alternative biomarkers to support and
complement CA-125 use is an unmet need.
In the last decade, several studies have demonstrated the potential
use of liquid biopsies for cancer detection and management. In OC
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
appears to be a promising diagnostic and/or prognostic biomarkers.
Here we carried out a literature search in NCBI PubMed from
January 2011 to May 2019, using ‘ovarian cancer’ together with ‘cir-
culating tumor cells’ or ‘circulating tumor DNA’. A total of 24 and 33
published articles were identified describing the analysis of CTCs and
ctDNA, respectively, for diagnosis, prognosis and/or monitoring in OC
patients. We summarized the findings of these studies, present the
https://doi.org/10.1016/j.canlet.2019.10.014
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current technologies utilised for analysis and the potential clinical ap-
plications and limitations of these techniques. We also discuss emerging
technologies and concepts, as well as the existing challenges for liquid
biopsy applications. Finally, we offer our perspective as to when the
information from liquid biopsies may be considered reliable and clini-
cally applicable.
2. Ovarian cancer CTCs
CTCs are tumor cells that are released from primary, metastatic or
recurrent tumors and can be identified in the peripheral blood of cancer
patients [11]. In OC, the presence of these CTCs in the blood of patients
provide useful diagnostic and prognostic information associated with
both primary and metastatic tumors [12–14].
2.1. Enrichment and detection methods
The ratio of CTCs to other cells in the blood is extremely low. Thus,
it is quite challenging to detect and differentiate CTCs from non-tumor
cells in whole blood. CTC enrichment techniques are employed in
combination with subsequent detection methods for evaluation of CTC
presence [11]. Various methods reported for the isolation of CTCs from
OC patients rely on either the; (1) physical properties of tumor cells
such as density, size, deformability or (2) biological properties such as
positive or negative label-dependent immunoaffinity enrichment tar-
geting specific surface proteins (Table 1).
Isolation methods based on physical properties include the use of
micro-fluidic platforms such as Parsortix™ [14], the Biotin/Ppy-micro-
fluidic and others [15,16]. Other methods include filter based size ex-
clusion like MetaCell® [12,13] and the tapered-slit membrane filters
(TSF) [17,18]. Other studies reported the use of density gradient cen-
trifugation for the isolation of OC CTCs [19,20].
The most common immunoaffinity-based CTC isolation method
used in OC is the FDA-approved CellSearch® system, which capture
CTCs of epithelial origin using EpCAM [21–23]. Similar methods em-
ploying immunomagnetic beads have also been utilised targeting a
variety of ligands such as EpCAM, HER2 and MUC1 [24]. Other novel
techniques such as the functional cell adhesion molecule (CAM) uptake-
cell enrichment method, have also been reported for CTC isolation in
OC [25,26] (Table 1). Moreover, the use of magnetic nanoparticles
targeting folic acid receptors on OC CTCs have also been reported
[27,28].
CTCs are detected in the enriched sample either by im-
munocytochemistry (ICC) [15–18,20–23,27–32] or by gene expression
analysis, mostly by real-time PCR (RT-PCR) [14,19,24,33–36]. Fluor-
escent in situ hybridization (FISH), has also been reported as a con-
firmatory test for identifying OC CTC with stem-cell like fusion genes
[20]. Studies using only ICC (14/24) for CTC quantification reported
detection rates ranging from 7.7 to 98%, while those that only used RT-
PCR (7/24) had a 14–91% detection rate, irrespective of sampling time
(Table 1). However, other studies (3/24) used a combination of the two
for the identification of potential CTCs, and had detection rates ranging
from 65 to 100% [12,13,26]. Thus, a combination of ICC and RT-PCR
techniques may increase the detection of CTCs.
Both epithelial (EpCAM/cytokeratin) and mesenchymal markers (N-
cadherin and vimentin) are used for detection of CTCs in OC
[15,16,32], which consistently show higher detection rates (≥90%)
compared to the use of epithelial markers only (CellSearch®) (≤60%)
[21–23]. However, the use of epithelial mesenchymal transition (EMT)
markers such as N-cadherin [32] and vimentin [15] to complement
EpCAM for CTC detection in OC may result in “false positives”, since
circulating endothelial cells also express these markers. Hence, efficient
negative exclusion need to be adopted to avoid false positives [32].
Similarly, leucocytes in the CTC enriched samples (Fig. 1), may also
express mesenchymal and stem cell markers [33]. Thus, single-cell
molecular characterization could be more accurate for assessing CTC
gene expression more broadly [33].
Overall, most studies did not report on sensitivity and specificity of
the assay used, which affects the comparison of the diagnostic perfor-
mance of different platforms employed for the detection and analysis of
OC CTCs. Therefore, the robustness and clinical validity of these tech-
niques across different platforms beyond the initial proof of concept,
warrants further study using larger sample sizes.
2.2. Molecular profiling of CTCs
Molecular profiling of CTCs in OCs has revealed a myriad of po-
tential biomarkers of diagnostic importance [12,13,33–36]. A study by
Kolostova et al., evaluated the heterogeneity of CTCs in OC patients and
identified EpCAM, WT1, MUC16, MUC1, KRT7, KRT18 and KRT19 as
genes that are highly specific for CTCs from OC, which are also asso-
ciated with tumorigenic characteristics [13].
Blassl et al. [33] performed a single-cell quantitative transcriptomic
profiling of a CTC from an OC patient, utilising gradient density for
initial cell enrichment, followed by CD45 depletion. They identified
EMT (Vimentin, N-cadherin, Snai2, CD117, and CD146) and stem cell
(CD44, ALDH1A1, Oct4 and Nanog) gene transcripts on the single CTC.
Similarly, other EMT-gene transcripts (PI3Kα, Akt-2 and Twist) were
demonstrated in OC CTCs [36]. Detection of EMT gene transcripts from
CTCs from patients can help inform clinicians about potential tumor
resistance, and may ultimately aid in developing personalized ap-
proaches to combat these mesenchymal tumor cells.
More applicable to clinical care, Kuhlmann et al. [34] indicated that
platinum-resistance could be predicted through the detection of ERCC1
(excision repair cross-complementation group 1) gene expression in
CTCs. ERCC1 which aids in the repairing of DNA-platinum adducts, was
an independent predictor of platinum resistance (OR=8.5; 95% CI,
1.7–43.6; p=0.010) in this study.
The above studies underscore that beyond CTC enumeration, mo-
lecular characterization may provide additional biological information
that could be used for prognostication or treatment decisions.
2.3. Cluster of CTCs
CTCs, especially epithelial CTCs, normally do not survive in per-
ipheral blood due to anoikis, a form of programmed cell death in an-
chorage-dependent cells, and haemodynamic sheer stress [37]. Never-
theless, EMT may circumvent death-inducing signals, allowing
mesenchymal cancer cells to thrive and metastasize even in the pre-
sence of therapy [36]. EMT transcription factors (EMT-TFs) such as Slug
and Snail, have been demonstrated to directly contribute to resistance
to platinum-based drugs such as cisplatin in OC patients [38].
Mesenchymal and epithelial CTCs can also form clusters and aid
collective migration to better enhance their chances of survival [39].
This has been widely accepted as a critical stage of CTC dissemination
through research studies in breast cancer CTCs [39,40]. In OC, micro-
emboli or clusters of CTCs (2–30 cells) were identified in 59% of pa-
tients in one study, and were significantly associated with platinum
resistance (p=0.0001), shorter progression free-survival (PFS) and
time to progression (TTP) [16]. The presence of CTC clusters were also
reported in another OC study, but limited details were provided re-
garding the association of CTC clusters and clinical outcomes [26].
Given the paucity of data on CTC clusters in OC, further investiga-
tion is warranted to address and precisely clarify the molecular path-
ways involved in this process. Nevertheless, EMT-TFs such as Snail and
ZEB [41], may be a potential target for the treatment of those peculiar,
resistance-prone and invasive CTC-hybrid phenotypes.
2.4. Diagnostic significance of CTCs in ovarian cancer
Studies have consistently shown that detection of CTCs in OC is
significantly associated with more advanced disease stage (III and IV)
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[18,19,24–26,34]. In a recent study by Zhang et al., the number of CTCs
found in stage I patients was significantly lower than those with stage
III and IV (p < 0.05) [24]. Similarly, a significant association
(p < 0.0001) was demonstrated between CTC number and tumor stage
in patients with advanced disease [25]. Compared to benign controls,
early stage (I and II) and late stage (III and IV) disease were 8.4 and
16.9 times more likely to have CTCs respectively [25]. More recently,
post-operative OC CTC count was significantly associated with the ad-
vanced stages than the early stage (p=0.010) [18]. Advanced stages
have higher tumor burden and thus, are able to shed higher numbers of
CTCs into circulation, which have the potential to establish metastatic
colonies at near or distant sites from the area of release. This may also
explain why patients at late stages have a high incidence of recurrence
and worse survival despite maximal efforts at debulking surgery.
The diagnostic performance of CTC detection methods through ICC
have a sensitivity ranging from 76 to 83% and a specificity of 55–95%
[15,17,25,30]. Amongst the six studies that used RT-qPCR for CTC
detection, only one reported on the diagnostic sensitivity and specificity
(22% and 85% respectively [19]), which were surprisingly lower than
that of ICC methods. A study that combined both detection methods
(ICC/RT-qPCR) reported a high sensitivity (83%) and specificity (97%)
[26]. To note, the discussed studies varied regarding the use of benign
[15,17,25,30] or healthy donors [19,26] as control groups. None-
theless, ICC methods seem to provide a reliable and accurate diagnosis
of OC, particularly at later stages.
2.5. CTC as a predictor of response to therapy and prognosis in ovarian
cancer
A number of studies also evaluated the utility of CTCs as a bio-
marker of chemotherapy response in OC (Table 1), and demonstrated
that CTC numbers significantly decline after chemotherapy (p < 0.05)
[19,22–24,26]. For example, a study demonstrated that the overall CTC
count decreased over time at a linear rate of 0.1 cell per month
(p < 0.0001) during chemotherapy [23]. Another study reported a
higher rate of CTC positivity after chemotherapy (19 and 27% pre- and
post-treatment, respectively) [35]. Additionally, a study showed that
after chemotherapy, CTCs were more likely (p=0.015) to be identified
in patients classified as non-responders than responders [20]. More-
over, platinum resistant patients had significantly (p < 0.05) higher
numbers of CTCs as compared to platinum sensitive patients [19].
Overall, these results suggest that CTCs may be a predictive marker for
response in OC to platinum-based chemotherapy. CTC release into
circulation could be hindered by chemotherapy, and this may differ
among individuals due to patient heterogeneity and tumor stage.
However, the lack of standardisation of methodology, and the absence
of large prospective studies are significant barriers for its im-
plementation into clinical practice.
Multiple studies have reported significant association between the
presence of OC CTCs and PFS or overall survival (OS), using specific
cut-off levels for CTC positivity [16,20,22,26,34,35]. For example,
previously untreated patients with advanced OC and high CTC count
(≥3) prior to chemotherapy had a significantly shorter PFS, compared
with patients with< 3 CTCs (p < 0.05) [16]. Similarly, patients with
persistent elevated CTC counts ≥2 at baseline and follow-up, had
shorter PFS (p=0.0024) and OS (p=0.0017), compared with patients
with< 2 CTCs [22]. Likewise, another study has also shown that in-
crease in CTCs has a high association with increased risk of progression
[26]. Other report, however, did not obtain significant association with
clinical outcome (PFS/OS) [18].
Overall, these studies demonstrate that patients with persistently
high CTCs have worse prognosis compared to those with negative CTCs
using either ICC or RT-PCR methods (Table 1). While different
thresholds for CTC positivity and detection methodologies were used, it
is clear that irrespective of the methodology utilised for detection, the
presence of CTCs may help in the prediction of survival outcomes in OC.
3. Circulating tumor DNA
Cell-free DNA (cfDNA) is released via necrosis or apoptosis of tumor
cells [42]. Currently, the exact mechanism of cfDNA release is unclear
but its levels has been shown to increase after excessive physical
Fig. 1. CTC and ctDNA detection methods and clinical applications in ovarian cancer.
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activity, inflammatory conditions and sepsis [42]. Nonetheless, cfDNA
levels in cancer patients is higher than in healthy individuals [6,42].
Plasma cfDNA emanating from the tumor is considered as circulating
tumor DNA (ctDNA) (Fig. 1).
Levels of ctDNA in OC are significantly associated with the con-
ventional serum biomarker CA-125 [43]. However, ctDNA levels were
found to be more specific, accurate and depicts a real-time picture of
tumor burden due to its short half-life [42]. Conversely, CA-125 can be
elevated in benign and non-specific inflammatory conditions [9], and
has a relatively longer half-life estimated to range from 9 to 44 days
[44]. Therefore, ctDNA may be a more reliable biomarker of disease
status and treatment response.
Most research involving ctDNA analysis in OC are currently focused
on high grade serous ovarian carcinoma (HGSOC) patients (Table 2).
Molecular analysis conducted by the TCGA network revealed a high
prevalence (90%) of somatic TP53 mutations in HGSOC tumors [45].
Previous studies targeting mutant TP53 in HGSOC patients have de-
monstrated high sensitivity (> 75%) and specificity (> 80%) for mu-
tant ctDNA detection [46–48]. Furthermore, TP53 mutant-ctDNA de-
tection rates in HGSOC patients have been reported to be relatively
high, ranging from 75 to 100% [47–55] (Table 2). Other studies ex-
amined gene fusion [56] and somatic copy number variations (CNV)
[52,54,57–59] as alternative targets for OC ctDNA detection. Lastly,
plasma ctDNA detection via BRCA1/2 mutation in OC, which has a
detection rate of ~25%, could also be exploited for analysis (Table 2)
[60].
3.1. ctDNA detection methods and analysis
Plasma ctDNA analysis capitalizes on the identification of cancer-
specific mutations identified by technologies such as digital PCR (dPCR)
and next generation sequencing (NGS). In OC, ctDNA analysis using
droplet dPCR has been shown to have a limit of detection at 0.002%,
with a high specificity (81%) and sensitivity (99%), accompanied by a
high detection rate (> 93%) [47]. However, pre-identification of mu-
tant gene targets is required. NGS on the other hand, relies on the
analysis of multiple DNA regions and their comparison to germline
sequence [51,60]. NGS-based approaches used in the analysis of ctDNA
in OC includes whole genome sequencing (WGS), whole exome se-
quencing (WES) and tagged-amplicon deep sequencing (TAm-Seq). The
limit of detection (~1%–0.03%) depends on the platform used
(Table 2). TAm-Seq is the most sensitive, detecting allelic frequencies as
low as 0.03% [61]. NGS methods can interrogate several loci, providing
comprehensive mutational profiling and may reveal clonal evolution as
patients undergoing treatment.
Analysis of ctDNA can also be used to identify cancer specific me-
thylation patterns in OC patients using techniques such as methylation-
specific PCR (MSP), microarray mediated methylation assay (M3-assay),
reduced representation bisulfite sequencing (RRBS), targeted ultra-high
coverage bisulfite sequencing (TUC-BS), real-time methylation specific
PCR (RT-MSP) and multiplex nested methylated specific PCR (MN-PCR)
[62–71] (Table 3).
MSP is the main detection method employed for detecting methy-
lated ctDNA in serum of OC patients [62,64,66,68–70,72]. Its limit of
detection has been reported to be as low as 0.01% [70], with high
sensitivity (> 85%) and specificity (> 90%) for the detection of dif-
ferentially methylated ctDNA [65,66,68]. However, bisulphite conver-
sion could potentially miss targeted DNA [68], especially loci that are
prone to random fragmentation during apoptosis such as the promoter
gene regions [73]. This is an important consideration for designing
assays for analysis of methylation in cfDNA.
Overall, different methods have been utilised to detect and quantify
ctDNA with high diagnostic sensitivity and specificity, as well as high
detection rates in advanced disease. However, a limited number of
studies have carried out orthogonal validation to corroborate the results
obtained.
3.2. ctDNA as a diagnostic tool
Plasma ctDNA has the potential to serve as a minimally invasive
diagnostic tool of cancer. In particular for OC, ctDNA have been de-
monstrated to have a better diagnostic performance than the conven-
tional biomarker CA-125 [48,51,57,74]. We identified nine studies
showing significantly higher rates of positivity and/or higher quantity
of ctDNA than non-malignant individuals, with corresponding high
sensitivity and specificity (Table 2). These studies demonstrated that
quantitative analysis of ctDNA has relatively high specificity (> 88%)
but varied in sensitivity (27–100%) for diagnosis of OC
[46–48,54,57,58,75–77]. However, some of these studies had small
sample size (≤10) [43,49,53,54,75,78], and others had highly selected
populations such as patients with BRCA1/2 mutations treated with
PARP inhibitors [50,79]. Large studies conducted by Phallen et al. [77]
and Cohen et al. [76] underscore the potential of ctDNA as a diagnostic
tool for OC. These studies reflect on the utility of the CancerSEEK [76]
and TEC-Seq [77] technologies to diagnose OC at ~97% sensitivity
and> 99% specificity.
In summary, ctDNA is a promising tool for evaluating tumor burden
in OC patients. However, further clarification is needed to define the
minimum tumor size detectable through ctDNA analysis. Moreover,
large prospective studies are needed to determine the clinical utility of
ctDNA detection for early diagnosis of OC and its impact on patient
outcomes.
3.3. Utility of ctDNA for prognostication, detecting residual disease and
monitoring of response to treatment
A few studies have evaluated the utility of ctDNA as a prognostic
biomarker for HGSOC. These studies have also demonstrated that
ctDNA dynamics correlate with response to adjuvant chemotherapy in
OC, and may predict progression or response earlier than CA-125
[46,48,80] or imaging [47]. Pereira et al. demonstrated that un-
detectable levels of ctDNA at 6 months following initial primary
treatment was associated with significantly improved PFS (p=0.001)
and OS (p < 0.05). The authors also showed that ctDNA detection had
a predictive lead time 7 months over CT scan [47].
In an exploratory analysis of TP53 mutations in the ctDNA of re-
lapsed HGSOC patients, Parkinson et al. reported that ctDNA was de-
tected at no less than 20 amplifiable copies per milliliter of plasma in
nearly all relapsed patients with disease volume>32 cm3. The study
also highlighted the prognostication ability of TP53 in HGSOC, de-
monstrating that a decrease of ≤60% in TP53 mutant allele fraction
after one cycle of chemotherapy was associated with poor response and
shorter time to progression (TTP), whereas a decrease of> 60% was
predictive of longer TTP [48].
Recent reports have also shown that persistence of TP53 gene var-
iants in ctDNA after neoadjuvant chemotherapy could be used to de-
termine minimal residual disease [51] and treatment response mon-
itoring [52,80] in OC patients. A case study by Martignetti et al.,
highlighted the possibility of detecting rare tumor-specific gene fusion
(FGFR2-FAM76A), using ctDNA [56]. The authors concluded that
ctDNA analysis was more sensitive and specific than the conversional
biomarker CA-125 when used for monitoring response to therapy in
advanced OC patients. Similarly, Harris et al. [43] demonstrated the
feasibility of using somatic chromosomal re-arrangements to identify
plasma ctDNA. Persistently detectable ctDNA levels post-surgery was
consistent with disease burden and risk of recurrence in OC patients,
while undetectable ctDNA levels were consistent with absence of de-
tectable disease. More recently, plasma ctDNA was found to be an in-
dependent factor of OS (p=0.025) and PFS (p=0.001) in a cohort of
OC patients with disease recurrence [54].
The strongest evidence to date on clinical utility of ctDNA in OC is
the identification of residual disease and the monitoring of treatment
response more accurately than the conventional imaging and CA-125
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methods. Implementation of liquid biopsy in this context could aid in
the selection of individuals who may be at greater risk of relapse, and
may be considered for alternative management approaches and po-
tential inclusion in appropriate clinical trials [51,80].
3.4. ctDNA for identification of treatment resistance
Selective pressure induced by treatment, whether platinum-based
chemotherapy or targeted therapy such as PARP-inhibitors, can cause
cancer cells to evolve, via additional gain or reversion of genetic al-
terations. For example, one study [46] reported the emergence of a de
novo mutation in the tyrosine kinase domain of EGFR in a HGSOC pa-
tient at disease relapse that was not present 15 months earlier in the
same patient, despite of a TP53 mutation at 85% allelic frequency. Si-
milarly, WES of plasma ctDNA in three OC patients revealed specific
gene mutations (RB1, MTOR, ZEB2, CES4A, BUB1, PARP8) that may
confer resistant to treatment with drugs such as cisplatin, paclitaxel and
liposomal doxorubin. Serial sampling measurements and quantification
of allele fractions in ctDNA led to the identification of these gene mu-
tations associated with the acquired resistance [75]. In a recent study
by Oikkonen et al., ERBB2 amplification was identified as a potential
mediator of resistance to platinum chemotherapy and ctDNA-guided
therapy using trastuzumab, increased response and aided tumor
shrinkage [52]. This study highlights a mark improvement in the
management of recurrent solid cancers such as OC, where repeat
biopsies may cause potential risk or complications.
Reversion mutations of BRCA1/2 detected in the plasma of OC pa-
tients were also associated with resistance to therapy (platinum/PARP
inhibitors) [50,61,79]. Weigelt et al. assessed the feasibility of ana-
lyzing cfDNA for detecting BRCA1/2 reversion mutations in advanced
OC patients previously treated with platinum and/or PARP inhibitors.
Immunoprecipitation and functional assay analysis demonstrated that
the reversion mutations restored the DNA repair functions previously
inactivated by the original BRCA1/2 mutation, leading to the observed
resistance in these patients [50]. Christie et al. also indicated that
BRCA1/2 reversion mutations can be detected in cfDNA of HGSOC
patients (3/16), albeit at lower frequency than through the analysis of
tumor samples (5/16). All cases with reversions had become resistant to
platinum/PARP-inhibitors at the time of blood collection. The authors
highlighted a patient who had a BRCA1/2 reversion mutation and did
not respond to platinum and a PARP inhibitor but that subsequently
had partial response to gemcitabine and bevacizumab treatment [79],
to underscore that detection of reversions can aid selection of more
suitable treatments.
Together, these data demonstrate the potential of ctDNA to detect
the emergence of escape mutations and reversion of BRCA1/2 muta-
tions. Regular monitoring through a liquid biopsy could aid the early
detection of resistance and the selection of alternative drugs. It may also
lead to personalized combinatorial therapy, including chemotherapies,
targeted therapies or immunotherapy that may target different onco-
genic drivers or reduce the emergence of resistance.
3.5. Diagnostic potential of promoter methylation in cfDNA
Promoter methylation resulting in epigenetic inactivation of tumor
suppressor genes has been demonstrated as an early event during the
pathogenesis of OC [68,69]. These changes such as hypermethylation in
promoter regions of ctDNA have been reported to possess diagnostic
potential [64–68,70,71]. Essentially, ctDNA methylation status in the
serum/plasma of OC patients could be useful for early detection and
help guide personalized treatment.
Patients with advanced disease (III-IV) have shown significantly
(p < 0.05) higher serum CA-125 than the early stages (I-II) but com-
parison of methylation patterns in both stages showed no significant
difference (p < 0.05). However, both early and advanced stage disease
showed a significant association (p < 0.05) with abnormal methyla-
tion of tumor suppressor genes when compared to normal healthy and
benign controls [65,68,69]. In another report, though CA-125 levels
were not computed, methylation patterns were still significantly dif-
ferent between OC patients and benign or healthy control groups [67].
These reports suggest that aberrant gene promoter methylation is an
early event in the development of OC that could aid the early detection
of malignancy.
Studies have shown the feasibility of detecting hypermethylation in
the promoters of the tumor suppressor genes RUNX3, TFP12 RASSF-1A
and 2A from serum and plasma samples for diagnosis of OC patients
[64–68,70,71]. These studies have alluded to the high diagnostic sen-
sitivity and specificity of these hypermethylated genes in patients
compared to normal healthy controls [64–68,70,71], indicating its di-
agnostic potential. However, it is important to note that markers ana-
lysed for these studies have been previously reported in other cancers.
In addition, Widschwendter et al. [57] found that their set of epigenetic
markers, including COL23A1, C2CD4D and WNT6, measured in serum
DNA had superior specificity compared to CA-125 (90.7% vs 87.1%)
but had lower sensitivity (82.8% vs 41.4%). From these studies, it ap-
pears that variations in diagnostic specificity and sensitivity can be
attributed to the epigenetic marker used for analysis. Identification of
highly specific ovarian cancer-specific methylated could improve the
utility of methylated ctDNA for early diagnosis in OC patients.
Of note, epigenetic analysis reported thus far mostly utilised serum,
compared to mutational ctDNA analysis which primarily uses plasma
(Tables 2 and 3). The disparity in the choice of biological material used
for epigenetic studies and mutant circulating DNA analysis in OC is yet
to be elucidated. Compared to that of plasma [64,67,71], serum-based
studies [63,65,66,68] showed consistently higher specificity (> 90%),
with sensitivity ranging from 41 to 91% with a corresponding high
detection rate.
Overall, methylation of promotor regions of tumor suppressor
genes, which consequently brings about their inactivation and repres-
sion, is a potential important aspect of OC pathogenesis that warrants
further study. Furthermore, elucidating epigenetic abnormalities by
cfDNA analysis may be used to select patients for targeted therapies
such as DNA methyltransferase inhibitors.
3.6. Value of methylated cfDNA for patient monitoring and prognostication
Existing data evaluated aberrant methylation patterns in OC cfDNA
for diagnostic efficiency and very few studies have evaluated its utility
for patient monitoring [57] and prognostication [58]. A study by
Widschwendter et al. [57] have demonstrated that reduction of me-
thylated ctDNA levels in OC patients after 2 cycles of chemotherapy was
associated with treatment response. Hypermethylation of promoter
regions of RASSF1A, have been reported to be associated with reduced
OS and disease relapse in the tumor but not in ctDNA [64]. Overall,
there is paucity of studies addressing the potential utility of methylated
markers for monitoring treatment response and prognostication of OC
patients.
4. Future directions
Our review of studies on ctDNA and CTC in OC patients identified
significant variability between studies, in terms of sample size, sam-
pling time, isolation and detection methods. Particularly concerning is
the lack of consensus for CTC analysis. Cut-off values used for con-
firming CTCs positivity varied across studies and platforms, which
could impact on the derived conclusions. Therefore, a more uniform
approach for CTC characterization and definitions of positivity is
needed to evaluate intra- and inter-laboratory reproducibility. This will
ultimately improve standardization across different CTC enrichment
and detection platforms. However, unlike ctDNA, CTCs can provide
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detailed information about the tumors at RNA and protein level, en-
abling further research to better our understanding of the metastatic
process.
Further basic research is needed to identify the role of CTC clusters
and mesenchymal/stem cells CTCs in disease progression. Isolation
platforms need to be optimized to minimize the shear stress that may
bring about the detachment of individual cells in the CTC cluster or loss
of EMT CTCs. In particular, it will be important to determine how
stromal interactions and cluster cell formation may aid CTC release,
especially in reactive stromal subtypes of OCs [81]. This could poten-
tially help unravel chemo-resistance molecular trajectories in the EMT
CTCs phenotypes which may lay a foundation for developing persona-
lized therapeutic approaches.
In addition to blood, peritoneal fluid [82,83] and uterine lavage
[84] have been used to obtain cell pellets that are used for the identi-
fication of common mutant genes (TP53, BRCA1 and BRCA2). Several
other bodily fluids, including urine, uterine lavage, ascites and perito-
neal fluids, have also been shown as source of tumor-derived material
that can be used to differentiate between OC patients and healthy or
benign individuals [84–88]. Further studies are needed to determine
the sensitivity and specificity of other non-invasive tests for diagnosis of
OC.
Early detection of malignancy is critical in reducing mortality and
morbidity. Technologies such as NGS and digital PCR allows the de-
tection of very low frequency events. However, sensitivity remains a
limiting factor for early stage disease, not only in terms of assay sen-
sitivity but also by the rate or potentially low amount of ctDNA shed by
small asymptomatic tumors that may not be easily detectable in a
reasonable volume of blood drawn [89]. In addition, early detection
through ctDNA assumes that all mutant DNA in blood is tumor derived.
However, clonal hematopoiesis, mainly the formation of a distinct
subset of blood cells with genetic alterations, has been observed in 10%
of cancer free individuals aged over 65 years and may persist for many
years [90]. While 40–60% of mutations arise randomly outside of
known driver genes, several genes are commonly mutated in clonal
hematopoiesis [77], amongst them is TP53 which is also relevant for
the diagnosis of HGSOC. Though earlier reports utilising samples from
uterine lavage demonstrated absence of mutations in women without
cancer [84], current studies have highlighted high background of driver
gene mutations in healthy controls [91,92]. Therefore, non-cancer de-
rived mutations may constitute a significant cause of false positivity for
mutant DNA detection. Thus, algorithms that account for clonal he-
matopoiesis (in blood) and regenerative defects (tissues) in NGS data is
required to achieve high specificity for mutant DNA analysis in gyne-
cological studies.
Several initiatives have emerged for early diagnosis through ctDNA
analysis. The CancerSEEK study [76] combines a machine-learning al-
gorithm with the analysis of specific mutations in cfDNA and of circu-
lating protein markers known to increase in certain cancers, to derive
an accurate diagnosis of eight cancer types. In particular, OC was de-
tected with a sensitivity of 98% and specificity of> 99%. The bio-
technology company GRAIL reported at the 2018 ESMO Conference
[93] results on 2402 prospectively collected samples from non-cancer
controls and newly diagnosed untreated patients. Amongst them, seven
OC patients were included, with 71% of them being positively identi-
fied. More recently, in ASCO 2019, GRAIL reported on their prototype
methylation technology that can detect the tumor tissue of origin with
high accuracy [94]. However, no data on ovarian cancer patients was
presented. As discussed above, hypermethylated promoter regions of
tumor suppressor genes could be used as a marker for detecting OC at
an early stage, since these genes have been shown to be significantly
methylated in both early (I and II) and advanced stage (III and IV)
[65,68,69]. Hence, future large prospective studies in early stage
ovarian cancer are key to demonstrate clinical validity of ctDNA ana-
lysis before they may be incorporated in routine clinical practice.
5. Conclusions
In conclusion, CTC enumeration coupled with molecular char-
acterization is a non-invasive tool that hold promise as a prognostic
marker for OC, identifying patients at greater risk of recurrence or
death. It may also have a role for monitoring response and post-treat-
ment surveillance after surgery or systemic therapies. Similarly, ctDNA
analysis demonstrates high concordance of mutation and epigenetic
changes seen in tumor biopsies, and can potentially track minimal re-
sidual disease during treatment with a higher sensitivity than CTCs.
Furthermore, both CTCs and ctDNA may help determine the emer-
gence of novel mutations or reversions that manifest as resistance
tumor subclones, ultimately leading to disease recurrence. Future ef-
forts are required for standardization of analysis platforms, and the
incorporation of liquid biopsies as a companion biomarker in large
therapeutic clinical trials. Finally, improvements in patient outcomes
are key to demonstrate the utility of these liquid biopsy modalities for
personalized cancer medicine.
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